EQL Pharma Reports Q2 2026/2027 Financial Results
EQL Pharma reported a rebound in second-quarter sales and EBITDA, citing temporary stock-out demand and a milestone payment related to Mellozzan. Write-downs weighed on gross margin; the company maintained full-year growth guidance of 15%.
EQL Pharma reported a rebound in sales and EBITDA for the second quarter of the 2026/2027 fiscal year. The company attributed this performance to temporary stock-out demand and a milestone payment related to Mellozzan. However, the company noted that write-downs negatively impacted its gross margin during the period. Management maintained its full-year growth guidance of 15%, emphasizing that future recovery remains dependent on reliable supply chains and improved execution of product launches.